ZIM Laboratories Limited (ZIM Labs), a research-driven pharmaceutical company focused on differentiated oral solid dosage forms, has entered into a Dossier License, Product Supply, and Technology Know-How License Agreement with Globalpharma Co., a leading UAE-based pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments, one of the region’s premier investment entities.

This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs’ proprietary Oral Thin Film technology platform, ThinOral. Under the agreement, Globalpharma will register and commercialize 10 OTF-based Pharmaceutical and Nutraceutical products developed by ZIM, catering to regional patient needs with advanced, user-friendly dosage forms.

Initially, ZIM Labs will supply bulk products while providing complete regulatory support for market registration in the UAE. Post-approval, ZIM will deliver ready-to-use powder mixes, enabling Globalpharma to undertake localized manufacturing and marketing of the finished formulations.

Sharing his views on the collaboration, Kamal, Director Finance of ZIM Laboratories Limited, added: “This collaboration represents a strong strategic fit and unlocks significant commercial potential for both parties. It reinforces our vision of building long-term value through global partnerships, while leveraging ZIM’s R&D excellence and Globalpharma’s strong regional footprint. Together, we aim to bring convenient, high-quality solutions to patients worldwide.” 

The partnership marks a pivotal milestone in ZIM Labs’ mission to make differentiated formulations globally accessible and reinforces its presence in the rapidly growing Middle Eastern Pharmaceutical market.